These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36347937)

  • 1. The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?
    Farshbaf A; Lotfi M; Zare R; Mohtasham N
    Pharmacogenomics J; 2023 May; 23(2-3):37-44. PubMed ID: 36347937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Factors as Predictors for Establishment of Patient Derived Head and Neck Squamous Cell Carcinoma Organoids.
    de Kort WWB; Millen R; Driehuis E; Devriese LA; van Es RJJ; Willems SM
    Head Neck Pathol; 2024 Jun; 18(1):59. PubMed ID: 38940869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.
    Driehuis E; Kolders S; Spelier S; Lõhmussaar K; Willems SM; Devriese LA; de Bree R; de Ruiter EJ; Korving J; Begthel H; van Es JH; Geurts V; He GW; van Jaarsveld RH; Oka R; Muraro MJ; Vivié J; Zandvliet MMJM; Hendrickx APA; Iakobachvili N; Sridevi P; Kranenburg O; van Boxtel R; Kops GJPL; Tuveson DA; Peters PJ; van Oudenaarden A; Clevers H
    Cancer Discov; 2019 Jul; 9(7):852-871. PubMed ID: 31053628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of head and neck squamous cell carcinoma.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):131-137. PubMed ID: 30893149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.
    Perréard M; Florent R; Divoux J; Grellard JM; Lequesne J; Briand M; Clarisse B; Rousseau N; Lebreton E; Dubois B; Harter V; Lasne-Cardon A; Drouet J; Johnson A; Le Page AL; Bazille C; Jeanne C; Figeac M; Goardon N; Vaur D; Micault E; Humbert M; Thariat J; Babin E; Poulain L; Weiswald LB; Bastit V
    BMC Cancer; 2023 Mar; 23(1):223. PubMed ID: 36894916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification.
    Millen R; De Kort WWB; Koomen M; van Son GJF; Gobits R; Penning de Vries B; Begthel H; Zandvliet M; Doornaert P; Raaijmakers CPJ; Geurts MH; Elias SG; van Es RJJ; de Bree R; Devriese LA; Willems SM; Kranenburg O; Driehuis E; Clevers H
    Med; 2023 May; 4(5):290-310.e12. PubMed ID: 37178682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
    Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
    J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the treatment sensitivity of patient-derived organoids with treatment outcomes in patients with head and neck cancer (SOTO): protocol for a prospective observational study.
    Vasiliadou I; Cattaneo C; Chan PYK; Henley-Smith R; Gregson-Williams H; Collins L; Wojewodka G; Guerrero-Urbano T; Jeannon JP; Connor S; Davis J; Pasto A; Mustapha R; Ng T; Kong A
    BMJ Open; 2024 Oct; 14(10):e084176. PubMed ID: 39389599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.
    Parikh AS; Yu VX; Flashner S; Okolo OB; Lu C; Henick BS; Momen-Heravi F; Puram SV; Teknos T; Pan Q; Nakagawa H
    Oral Oncol; 2023 Mar; 138():106330. PubMed ID: 36773387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma.
    Fang R; Iqbal M; Chen L; Liao J; Luo J; Wei F; Wen W; Sun W
    Aging (Albany NY); 2021 Apr; 13(8):11507-11527. PubMed ID: 33867351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
    Mudianto T; Campbell KM; Webb J; Zolkind P; Skidmore ZL; Riley R; Barnell EK; Ozgenc I; Giri T; Dunn GP; Adkins DR; Griffith M; Egloff AM; Griffith OL; Uppaluri R
    Clin Cancer Res; 2021 Apr; 27(8):2326-2339. PubMed ID: 33547198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in patient-derived tumor organoids for reconstructing TME of head and neck cancer.
    Chen L; Chen Y; Ge L; Zhang Q; Meng J
    J Oral Pathol Med; 2024 Apr; 53(4):238-245. PubMed ID: 38561906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
    Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
    J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy.
    Gu Z; Yao Y; Yang G; Zhu G; Tian Z; Wang R; Wu Q; Wang Y; Wu Y; Chen L; Wang C; Gao J; Kang X; Zhang J; Wang L; Duan S; Zhao Z; Zhang Z; Sun S
    Sci Transl Med; 2022 Sep; 14(661):eabo5987. PubMed ID: 36070368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging organoid models: leaping forward in cancer research.
    Fan H; Demirci U; Chen P
    J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.